The impact of diacetylmorphine on hypothalamic-pituitary-adrenal axis activity and heroin craving in heroin dependence

European Addiction Research

Volumn 18, Issue 3, 2012, Pages 116-123

  Gerber, Hana ^a,c   Borgwardt, Stefan J ^a   Schmid, Otto ^a   Gerhard, Urs ^a   Joechle, Wolfgang ^b   Riecher Rössler, Anita ^a   Wiesbeck, Gerhard A ^a   Walter, Marc ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Adrenocorticotropic hormone; Cortisol; Craving; Diacetylmorphine; Heroin assisted treatment; Hypothalamic pituitary adrenal axis; Opioid dependence; Stress

Indexed keywords

CORTICOTROPIN; DIAMORPHINE; HYDROCORTISONE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG DEPENDENCE TREATMENT; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEROIN CRAVING QUESTIONNAIRE; HEROIN DEPENDENCE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SALIVA LEVEL; STRESS; WITHDRAWAL SYNDROME;

ADULT; BEHAVIOR, ADDICTIVE; CROSS-OVER STUDIES; FEMALE; HEROIN; HEROIN DEPENDENCE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84856140376     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000334411     Document Type: Article

References (52)

1. Leshner AI: Addiction is a brain disease, and it matters. Science 1997; 278: 45-47. (Pubitemid 27446268)
2. Le Moal M, Koob GF: Drug addiction: Pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol 2007; 17: 377-393. (Pubitemid 46497657)
3. McKay JR, Alterman AI, Mulvaney FD, Koppenhaver JM: Predicting proximal factors in cocaine relapse and near miss episodes: Clinical and theoretical implications. Drug Alcohol Depend 1999; 56: 67-78. (Pubitemid 29295380)
4. Epstein DH, Willner-Reid J, Vahabzadeh M, Mezghanni M, Lin J-L, Preston KL: Realtime electronic-diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. Arch Gen Psychiatry 2009; 66: 88-94.
5. Childress AR, Ehrman R, McLellan AT, MacRae J, Natale M, O'Brien CP: Can induced moods trigger drug related responses in opiate abuse patients? J Subst Abuse Treat 1994; 11: 17-23. (Pubitemid 24113136)
6. Koob GF, Le Moal M: Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24: 79-129.
7. Piazza PV, Le Moal M: The role of stress in drug self-administration. Trends Pharmacol Sci 1998; 19: 67-74.
8. Kiefer F, Wiedemann K: Neuroendocrine pathways of addictive behaviour. Addict Biol 2004; 9: 205-212. (Pubitemid 39491045)
9. Brown TT, Wisniewski AB, Dobs AS: Gonadal and adrenal abnormalities in drug users: Cause or consequence of drug use behavior and poor health outcomes. Am J Infect Dis 2006; 2: 130-135.
10. Kreek MJ, LaForge KS, Butelman E: Pharmacotherapy of addictions. Nat Rev Drug Discov 2002; 1: 710-726. (Pubitemid 37361544)
11. Schluger JH, Bart G, Green M, Ho A, Kreek MJ: Corticotropin-releasing factor testing reveals a dose-dependent difference in methadone maintained versus control subjects. Neuropsychopharmacology 2003; 28: 985-994.
12. Eisenman AJ, Fraser HF, Sloan J, Isbell H: Urinary 17-ketosteroids during a cycle of addiction to morphine. J Pharmacol Exp Ther 1958; 124: 305-311.
13. Eisenman AJ, Fraser HF, Brooks JW: Urinary excretion and plasma levels of 17-hydroxycorticosteroids during a cycle of addiction to morphine. J Pharmacol Exp Ther 1961; 132: 226-231.
14. Facchinetti F, Volpe A, Farci G, Petraglia F, Porro CA, Barbieri G, Cioni A, Balestrieri A, Genazzani AR: Hypothalamus-pituitaryadrenal axis of heroin addicts. Drug Alcohol Depend 1985; 15: 361-366.
15. George JM, Reier CE, Lanese RR, Rower JM: Morphine anesthesia blocks cortisol and growth hormone response to surgical stress in humans. J Clin Endocrinol Metab 1974; 38: 736-741.
16. Ho WKK, Wen HL, Fung KP, Ng YH, Au KK, Ma L: Comparison of plasma hormonal levels between heroin-addicted and normal subjects. Clin Chim Acta 1977; 75: 415-419. (Pubitemid 8063621)
17. Wisniewski AB, Brown TT, John M, Cofranceso J Jr., Golub ET, Ricketts EP, Wand G, Dobs AS: Cortisol levels and depression in men and women using heroin and cocaine. Psychoneuroendocrinology 2006; 31: 250-255. (Pubitemid 41740444)
18. Rao U, Hammen CL, Poland RE: Mechanism underlying the comorbidity between depressive and addictive disorders in adolescents: Interactions between stress and HPA activity. Am J Psychiatry 2009; 166: 361-369.
19. Walter M, Gerhard U, Gerlach M, Weijers H-G, Boening J, Wiesbeck GA: Cortisol concentrations, stress-coping styles after withdrawal, and long-term abstinence in alcohol dependence. Addict Biol 2006; 11: 157-162. (Pubitemid 46696808)
20. Schäfer I, Teske, L, Thüsing-Schulze J, Homann K, Reimer J, Haasen C, Hissbach J, Wiedemann K: Impact of childhood trauma on hypothalamus-pituitary-adrenal axis activity in alcohol-dependent patients. Eur Addict Res 2010; 16: 108-114.
21. Gerra G, Leonardi C, Cortese E, Zaimovic A, Dell'Agnello G, Manfredini M, Somaini L, Petracca F, Caretti V, Baroni C, Donnini C: Adrenocorticotropic hormone and cortisol plasma levels directly correlate with childhood neglect and depression measures in addicted patients. Addict Biol 2008; 13: 95-104. (Pubitemid 351202138)
22. Camí J, Gilabert M, San L, De La Torre R: Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts. Br J Addict 1992; 87: 1145-1151.
23. Culpepper-Morgan JA, Kreek MJ: Hypothalamic-pituitary-adrenal axis hypersensitivity to naloxone in opioid dependence: A case of naloxone-induced withdrawal. Metabolism 1997; 46: 130-134. (Pubitemid 27078754)
24. Volavka J, Cho D, Mallya A, Baumann J: Naloxone increases ACTH and cortisol levels in man. N Engl J Med 1979; 300: 1056-1057. (Pubitemid 9193267)
25. Kreek MJ: Opiates, opioids and addiction. Mol Psychiatry 1996; 1: 232-254. (Pubitemid 126441297)
26. Kreek MJ, Koob GF: Drug dependence: Stress and dysregulation of brain reward pathways. Drug Alcohol Depend 1998; 51: 23-47. (Pubitemid 28353754)
27. Kreek MJ, Raghunath J, Plevy S, Hamer D, Schneider B, Hartmann N: ACTH, cortisol andα-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 1984; 5: 277-278. (Pubitemid 15163382)
28. Cushman Jr. P, Kreek MJ: Some endocrinological observations in narcotic addicts; in Zimmerman E, George R (eds): Narcotics and the Hypothalamus. New York, Raven Press, 1974, pp 161-173.
29. Kreek MJ, Hartman N: Chronic use of opioids and antipsychotic drugs: Side effects, effects on endogenous opioids, and toxicity. Ann NY Acad Sci 1982; 398: 151-172. (Pubitemid 13026044)
30. Walter M, Wiesbeck GA, Bloch N, Aeschbach S, Olbrich HM, Seifritz E, Dürsteler-MacFarland KM: Psychobiological responses to drug cues before and after methadone intake in heroin dependent patients: A pilot study. Eur Neuropsychopharmacol 2008; 18: 390-393.
31. Walter M, Wiesbeck GA, Degen B, Albrich J, Oppel M, Schulz A, Schächinger H, Dürsteler-MacFarland KM: Heroin reduces startle and cortisol response in opioid-maintained heroin-dependent patients. Addict Biol 2011; 16: 145-151.
32. Uchtenhagen A: Heroin-assisted treatment in Switzerland: A case study in policy change. Addiction 2010; 105: 29-37.
33. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A: Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001; 358: 1417-1420. (Pubitemid 33055744)
34. Dürsteler-MacFarland KM, Stohler R, Moldovanyi A, Rey S, Basdekis R, Gschwend P, Eschmann S, Rehm J: Complaints of heroinmaintained patients: A survey of symptoms ascribed to diacetylmorphine. Drug Alcohol Depend 2006; 81: 231-239. (Pubitemid 43152449)
35. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT: Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009; 361: 777-786.
36. van den Brink W, Hendricks VM, Blanken P, Koeter MWJ, van Zwieten BJ, van Ree JM: Medical prescription of heroin to treatment resistant heroin addicts: Two randomised controlled trials. BMJ 2003; 327: 310.
37. Blanken P, Hendriks VM, Koeter MVJ, van Ree JM, van den Brink W: Matching of treatment resistant heroin-dependent patients to medical prescription of heroin or oral methadone treatment: Results from two randomized controlled trials. Addiction 2005; 100: 89-95.
38. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D: Heroin-assisted treatment for opioid dependence. Randomized controlled trial. Br J Psychiatry 2007; 191: 55-62. (Pubitemid 47035182)
39. Verthein U, Bonorden-Kleij K, Degwitz P, Dilg C, Köhler WK, Passie T, Soyka M, Tanger S, Vogel M, Haasen C: Long-term effects of heroin-assisted treatment in Germany. Addiction 2008; 103: 960-966. (Pubitemid 351703473)
40. Tiffany ST, Fields L, Singleton E, Haertzen C, Henningfield JE: The development of a heroin craving questionnaire. Purdue University, 1993, unpublished manuscript.
41. Stitzer ML, Sigmon SC: Other substance use disorders: Prevalence, consequences, detection and management; in Strain EC, Stitzer ML (eds): The Treatment of Opioid Dependence. Baltimore, John Hopkins University Press, 2006, pp 365-397.
42. Kirschbaum C, Pierke KM, Hellhammer DH: The 'Trier Social Stress Test' -a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993; 28: 76-81. (Pubitemid 23283755)
43. Dickerson SS, Kemeny ME: Acute stressors and cortisol responses: A theoretical integration and synthesis of laboratory research. Psychol Bull 2004; 130: 355-391. (Pubitemid 38614661)
44. Tessner KD, Walker EF, Hochman K, Hamann S: Cortisol responses of healthy volunteers undergoing magnetic resonance imaging. Hum Brain Mapp 2006; 27: 889-895. (Pubitemid 44685001)
45. Peters S, Cleare AJ, Papadopoulos A, Fu CHY: Cortisol responses to serial MRI scans in healthy adults and in depression. Psychoneuroendocrinology 2011; 36: 737-741.
46. Muehlhan M, Lueken U, Wittchen HU, Kirschbaum C: The scanner as a stressor: Evidence from subjective and neuroendocrine stress parameters in the time course of a functional magnetic resonance imaging session. Int J Psychophysiol 2011; 79: 118-126.
47. Walter M, Gerhard U, Duersteler-MacFarland KM, Weijers H-G, Boening J, Wiesbeck GA: Social factors but not stress-coping styles predict relapse in detoxified alcoholics. Neuropsychobiology 2006; 54: 100-106. (Pubitemid 46143892)
48. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ: Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcome. Arch Gen Psychiatry 2006; 63: 324-331. (Pubitemid 43345357)
49. Stohler R, Dürsteler KM, Störmer R, Seifritz E, Hug I, Sattler-Mayr J, Müller-Spahn F, Ladewig D, Hock C: Rapid cortical hemoglobin deoxygenation after heroin and methadone injection in humans: A preliminary report. Drug Alcohol Depend 1999; 57: 23-28. (Pubitemid 29452952)
50. Frick U, Rehm J, Zullino D, Fernando M, Wiesbeck G, Amman J, Uchtenhagen A: Long-term follow-up of orally administered diacetylmorphine substitution treatment. Eur Addict Res 2010; 16: 131-138.
51. Gerber H, Borgwardt SJ, Gerhard U, Riecher-Rössler A, Wiesbeck GA, Walter M: Stress und Stressreaktivität bei der Opioidabhängigkeit. Ein Überblick (Stress and stress reactivity in opioid dependence). Schweiz Arch Neurol 2011; 162: 239-245.
52. Haasen C, Verthein U, Eiroa-Orosa FJ, Schäfer I, Reimer J: Is heroin-assisted treatment effective for patients with no previous maintenance treatment? Results from a German randomised controlled trial. Eur Addict Res 2010; 16: 124-130.